Biotech startups in Massachusetts, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
| Neurable | Boston | Series A | $35.0M | 2025-12-19 |
| VideaHealth | Boston | Series B | $40.0M | 2025-01-28 |
| ConcertAI | Cambridge | Series C | $150.0M | 2022-03-29 |
| Ascidian Therapeutics | Boston | Series A | $40.0M | 2023-11-08 |
| Biobot Analytics | Cambridge | Series A | $13.4M | 2025-06-06 |
| Dyno Therapeutics | Cambridge | Series A | $100.0M | 2021-05-06 |
8 rows of the CSV in 5 of its 18 columns.
- The 751 biotech startups in Massachusetts, United States have raised $47.7B in total.
- 118 of them closed their most recent round in the last 12 months, $4.3B combined.
- The largest of those rounds is Solstice Oncology's $225.0M Series A, dated September 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- RA Capital Management is an investor in 12 of them, more than any other fund.
- Health care is the most common other sector, with 652 companies (87%).
- 35% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (46% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 751| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| Arkea Bio | Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. | Biotech | Charlestown | Series A | $15.0M | 2026-09-29 | $60.5M | Breakthrough Energy Ventures, Overview, Rabo Ventures | 11 to 50 | 2021 |
| Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| INIA Biosciences | INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. | Biotech | Boston | Seed | $1.5M | 2026-09-08 | $1.5M | MassChallenge, MedTech Innovator | 1 to 10 | 2020 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| Remedium Bio | Remedium Bio develops gene therapy treatments for various diseases. | Biotech | Needham | Series A | $10.0M | 2026-08-10 | $13.8M | National Science Foundation, MicroVentures, Longevitytech.fund +1 | 11 to 50 | 2020 |
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Boston | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Xellar Biosystems | Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. | Artificial intelligence | Newton | Series A | $29.5M | 2026-06-30 | $93.2M | Legend Capital, Tiantu Capital, Zhengxuan Investment +1 | 11 to 50 | 2022 |
| Portal | Portal engineers cells to develop new treatments and therapies. | Biotech | Watertown | Seed | $9.0M | 2026-06-18 | $25.7M | Pear VC, Page One Ventures, IA Ventures +2 | 11 to 50 | 2023 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Cambridge | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Boston | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Cambridge | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
| Gelmedix | Gelmedix develops a biomaterial platform that improves drug delivery for complex eye treatments. | Biotech | Newton | Seed | $13.0M | 2026-02-17 | $15.4M | Safar Partners, EQx Fund, HTL Innovations | 1 to 10 | 2020 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Cambridge | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| STRM.BIO | STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. | Biotech | Cambridge | Seed | $8.0M | 2026-01-07 | $10.1M | Bill & Melinda Gates Foundation, NYBC Ventures, NCATS | 11 to 50 | 2019 |
| Myrtelle | Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. | Biotech | Wakefield | Series B | $30.5M | 2025-12-23 | $57.6M | Panacea Venture | 11 to 50 | 2020 |
| Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Boston | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| Biometry | Biometry develops diagnostic tools for patients with chronic respiratory conditions. | Artificial intelligence | Boston | Seed | $2.2M | 2025-12-19 | $7.8M | MassChallenge, Elevate Ventures, Sidecar Angels +1 | 11 to 50 | 2013 |
Table 1. Biotech startups in Massachusetts, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 751.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 2 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 3 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 4 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 5 | CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| 6 | Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| 7 | Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| 8 | Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| 9 | Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| 10 | Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
Table 2. Biotech startups in Massachusetts, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 12 | 2% | 4 | Delix Therapeutics, Superluminal Medicines, Terrestrial Bio |
| 2 | Google Ventures | Corporate venture arm | San Francisco, United States | 9 | 1% | 2 | Cerevance, Prudentia Sciences |
| 3 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 8 | 1% | 3 | Remedium Bio, Kytopen, Neurable |
| 4 | F-Prime | Venture capital firm | Cambridge, United States | 7 | 1% | 1 | Nocion Therapeutics |
| 5 | Y Combinator | Startup accelerator | Mountain View, United States | 7 | 1% | ||
| 6 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 7 | 1% | 2 | Triveni Bio, Kytopen |
| 7 | MassChallenge | Startup accelerator | Boston, United States | 7 | 1% | 2 | INIA Biosciences, Biometry |
| 8 | Polaris Partners | Private equity firm | Boston, United States | 6 | 1% | 1 | Triveni Bio |
| 9 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 5 | 1% | ||
| 10 | Invus | Private equity firm | New York, United States | 5 | 1% | 1 | Triveni Bio |
| 11 | Alumni Ventures | Angel group | Manchester, United States | 5 | 1% | ||
| 12 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 5 | 1% | ||
| 13 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 4 | 1% | 1 | Sanegene Bio |
| 14 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 4 | 1% | 2 | Ratio Therapeutics, Precede Biosciences |
| 15 | Pillar VC | Venture capital firm | Boston, United States | 4 | 1% |
Table 3. Biotech startups in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 652 | 87% | $43.6B |
| Software | 109 | 15% | $5.7B |
| Artificial intelligence | 70 | 9% | $4.4B |
| Hardware | 24 | 3% | $755.8M |
| Commerce | 3 | 0% | $75.6M |
| Energy | 3 | 0% | $7.8M |
| Education | 2 | 0% | $42.7M |
| Cybersecurity | 2 | 0% | |
| Fintech | 2 | 0% | $155K |
Table 4. Biotech startups in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 5 | 4% | $171.8M |
| October 2026 | 6 | 5% | $340.9M |
| September 2026 | 12 | 10% | $473.4M |
| August 2026 | 12 | 10% | $444.1M |
| July 2026 | 4 | 3% | $128.0M |
| June 2026 | 15 | 13% | $536.1M |
| May 2026 | 4 | 3% | $149.7M |
| April 2026 | 11 | 9% | $403.2M |
| March 2026 | 12 | 10% | $341.1M |
| February 2026 | 4 | 3% | $65.4M |
| January 2026 | 19 | 16% | $640.5M |
| December 2025 | 10 | 8% | $387.6M |
| November 2025 | 4 | 3% | $199.7M |
Table 7. Biotech startups in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 104 | 14% | $3.7B |
| 2025 | 98 | 13% | $4.2B |
| 2024 | 67 | 9% | $3.0B |
| 2023 | 65 | 9% | $3.8B |
| 2022 | 68 | 9% | $3.1B |
| 2021 | 74 | 10% | $2.8B |
Table 8. Biotech startups in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 95 | 13% |
| 2020 to 2022 | 169 | 23% |
| 2015 to 2019 | 244 | 33% |
| 2010 to 2014 | 110 | 15% |
| Before 2010 | 126 | 17% |
Table 9. Biotech startups in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 250 | 34% |
| 11 to 50 | 341 | 46% |
| 51 to 100 | 82 | 11% |
| 101 to 250 | 41 | 6% |
| 251 to 500 | 10 | 1% |
| 501 to 1,000 | 6 | 1% |
| 1,001 to 5,000 | 2 | 0% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 2 | 0% |
Table 10. Biotech startups in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 751 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 751 rows: 110 have no round amount, 0 no city and 103 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Massachusetts, United States are on the list?
- 751, in the file dated 16 November 2026. 118 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 751 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.